The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?

Affiliations

• ¹ Neuroscience Research, Randwick, New South Wales, Australia.
• ² Department of Psychology, University of New South Wales, Sydney, New South Wales, Australia.
• ³ Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.
• ⁴ MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK.
• ⁵ University of Kentucky, Lexington, Kentucky, USA.
• ⁶ Center for Studies on the Prevention of Alzheimer's Disease (PREVENT-AD), Verdun, Québec, Canada.
• ⁷ OPTIMA, Department of Pharmacology, University of Oxford, Oxford, UK.
• ⁸ Departments of Medicine and Neurology, University of Southern California, Los Angeles, California, USA.
• ⁹ Molecular and Clinical Sciences Research Institute, St Georges, University of London, London, UK.
• ¹⁰ Department of Neurology, St George's Hospital, London, UK.
• ¹¹ Bristol Medical School University of Bristol, Bristol, UK.
• ¹² Guys and St Thomas' NHS Foundation Trust, London, UK.
• ¹³ The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia.